Financial Results
LianBio Announces Completion of Strategic Review
The Company currently anticipates a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024.
Aesthetic Medical International Reports First Half of 2023 Unaudited Financial Results
Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, announced its unaudited financial results for the six months ended June 30, 2023.
LifeTech Scientific Corporation (1302.HK) Announces 2023 Interim Results
LifeTech Scientific Corporation (1302.HK) Announces 2023 Interim Results
Syngenta Group Reports H1 2023 Results
Syngenta Group today announced financial results for the first half and the second quarter of 2023.
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
Adagene reported financial results for the six months ended June 30, 2023 and provided corporate updates.
Jacobio Pharma Announces 2023 Interim Results
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced its 2023 interim results.
InnoCare Releases 2023 Interim Results and Business Highlights
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
Akeso (9926. HK) released its 2023 interim performance: the Company achieved financial profitability for the first time in the first half of 2023
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023.
Zylox-Tonbridge Reveals 2023 Interim Financial Results: Revenue Surges 50.7% YOY to 230 Million Yuan, Gross Profit Climbs to 171 Million Yuan
Zylox-Tonbridge released its financial results for the first half of 2023.
